COSCIENS Biopharma Inc., a life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally. The company lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications. It has a license agreement with NK MEDITECH Ltd. and Er-Kim Pharmaceuticals Bulgaria Eood for the development and commercialization of macimorelin. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.